This Pharma Company’s Gamble Might Finally Be Paying Off
Pfizer’s post-COVID identity wasn’t immediately apparent. It came to light gradually—through cautious pronouncements, data sets, and one very costly oncology wager. With good reason, the $43 billion purchase…










